Cleerly ISCHEMIA vs iCAC Device
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a detailed, non-invasive assessment of coronary artery ischemia, plaque characteristics, and stenosis severity from a CCTA scan. This tool is ideal for guiding personalized diagnosis and treatment planning, especially when functional significance of coronary lesions needs to be determined.
View Cleerly ISCHEMIA →Choose iCAC Device if…
Choose Bunkerhill Health's iCAC Device if your primary goal is opportunistic identification and quantification of coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans. This tool is best suited for early cardiovascular disease detection and risk stratification, leveraging existing imaging data without the need for dedicated cardiac studies.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | iCAC Device |
|---|---|---|
| Pricing | Contact for details | Contact for pricing |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA offers a web-based platform with comprehensive interactive reports and integrates with PowerScribe via API, a common radiology reporting system. This suggests a highly integrated and interactive user experience for reviewing and utilizing diagnostic results within existing clinical workflows.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides a more comprehensive and advanced clinical assessment by determining ischemia likelihood, non-invasive FFR, and detailed plaque characterization from CCTA scans, directly aiding personalized diagnosis and treatment planning. While iCAC offers valuable early detection via CAC quantification, Cleerly's output provides deeper, more immediate actionable insights for managing existing disease.
Pricing & Value
TieBoth tools require direct contact with the vendor for pricing details, making it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition based on the available information. While Cleerly ISCHEMIA mentions billability under a Category I CPTu00ae code, this does not provide specific pricing for comparison.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA) in its structured facts, which are crucial for enterprise adoption in healthcare. Tool B requires contacting the vendor for these essential details, indicating less upfront transparency on these critical aspects.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates higher innovation by offering non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization, which provide a more advanced functional and morphological assessment of coronary artery disease. While Bunkerhill's opportunistic CAC detection from routine CT scans is innovative for population health, Cleerly's capabilities push the diagnostic boundaries further.
Support & Docs
Cleerly ISCHEMIACleerly provides more explicit information regarding its client support channels, including a dedicated form for technical support and stated operating hours (Monday-Friday, 10 am ET to 6 pm ET). This indicates a more structured and transparent approach to customer assistance compared to the general contact information provided for Bunkerhill Health.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | iCAC Device |
|---|---|---|
| Tool Name | Cleerly ISCHEMIA | iCAC Device |
| Company | Cleerly | Bunkerhill Health |
| Primary Analysis Focus | Likelihood of coronary artery ischemia at a vessel level, coronary plaque characterization, stenosis severity assessment. | Detects and quantifies coronary artery calcium (CAC). |
| Input Scan Type | CCTA scans | Routine, non-contrast, non-gated chest CT scans |
| Key Output/Findings | Vessel-level ischemia likelihood, non-invasive fractional flow reserve (FFR) estimation, coronary plaque characterization (volume, type, location), stenosis severity assessment, 3D digital models of coronary arteries, comprehensive interactive web-based reports. | Presence and quantity of coronary artery calcium (CAC), visual representation of estimated CAC segmentation, exact and four-category quantitative estimates of CAC burden in Agatston units. |
| Integration Capabilities | Integration with PowerScribe via API | Integrates with PACS or DICOM router; integrates with EHRs via the Carebricks platform. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and iCAC Device.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or iCAC Device
Backers
Who funded each tool's parent company.